Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty

Mayo Clinic

Status and phase

Begins enrollment in 3 months

Phase 4

Conditions

Arthroplasty

Treatments

Drug: Oral Tranexamic Acid

Study type

Interventional

Funder types

Other

Identifiers

NCT06832878

24-008865

Details and patient eligibility

About

The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.

Enrollment

101 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Adults aged > 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
Written informed consent
Patients undergoing primary THA diagnosis of end-stage osteoarthritis
Patients receiving spinal anesthesia
Patients being discharged on postoperative day 1

Exclusion Criteria

Patients with a TXA allergy
Patients undergoing revision procedures
Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis
Patients receiving general anesthesia
Patients being discharged on the same day of surgery
Cancer patients
Patients with a history of prior VTE event
Patients on preoperative anticoagulants other than ASA
Pregnant patients (All women of child bearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
Female patients who are on hormonal contraception
Patients with history of retinal vein or artery occlusion